Why clinical trials matter?
The strategic goal of Hamlet Pharma is to develop novel cancer treatments for patients who currently lack therapeutic options. Conducting clinical trials is crucial to reach primary goals such as evaluating the therapeutic window for HAMLET in bladder cancer. We also aim to gain new insights that facilitate the drug development for Alpha1H and the diversification of our activities to include other indications.
The Phase I/II Clinical Trial In Patients With Bladder Cancer
Development Plan Achievements
The discovery of HAMLET defines a new class of cancer drugs with broad effects against cancers of different origin and a high degree of selectivity. Our aim is to prove the efficacy of HAMLET therapy and to develop drugs that kill tumour cells with greater precision than current drugs.
Outcome of the Phase I/II trial in patients with bladder cancer.
Hamlet Pharma Ltd. is making great progress and has just concluded the first part of a clinical trial in patients with bladder cancer. Drug development often takes many years, due to complex development and approval processes. Based on our extensive prior experience, the drug candidate, Alpha1H, has passed a number of important milestones in a relatively short time and with moderate cost.
The results of the clinical trial will be announced shortly.
The HAMLET Story
A research group in Lund, led by Professor Catharina Svanborg discovered in 1995 that a component of human breast milk kills tumor cells without harming mature, healthy cells.
Since the discovery, the research team has successfully worked to characterize the HAMLET structure, its mechanisms and treatment effects in animal models and in patients. HAMLET´s tumor killing abilities have since the discovery been confirmed by several international research groups working on different aspects of HAMLET.
The research results have been published in prestigious journals like The New England Journal of Medicine, GUT, Nature Reviews Gastroenterology and PNAS (Proceedings of the National Academy of Science, USA).About Hamlet Pharma
HAMLET offers a unique vision for the improvement of cancer-specific therapies.
HAMLET is a tumoricidal protein-lipid complex, formed by two GRAS (generally regarded as safe) molecules present in human milk. The novel therapeutic entity HAMLET is formed when the human milk protein alpha-lactalbumin undergoes a conformational change and binds to oleic acid.
Global Press Coverage
Top-tier press articles of HAMLET Pharma around the world
“Looking down the microscope at the dying tumor cells, we were quite excited, especially when the experiment was repeated and showed the same effect twice. We had used non cancerous cells for a long time in similar experiments and they had not died... Hamlet is ready to become a new drug.”Daily Telegraph
”Scientists are testing a modified protein found in breast milk to see whether it can be used to treat cancer. Researchers using a synthetic version of the chemical at Lund University, Sweden, are building on studies begun in 1995 when compounds derived from breast milk seemed to kill cancer cells without harming healthy cells. Results from the first trial, in Prague, on patients with bladder cancer are expected in May or June. It is hoped the drug may also be effective in tackling colon cancer and brain tumors.The Times
“There’s something magical about Hamlet’s ability to target tumour cells and kill them.”Daily Mail
”The final results include a range of very exciting, molecular technologies and tissue analyses that will provide more precise tools to define the drug effect in each patient. A positive outcome of the bladder cancer study would help reinforce the potential of this new type of cancer therapy.South China Morning Post
“We were looking for novel antimicrobial agents, and new breast milk is a very good source of these. To our amazement, when we added this compound of milk, the tumour cells died. It was a totally serendipitous discovery.”Daily Mail
“It’s a bit like pouring cement on (cancer) cells. They just can’t make new molecules and survive any longer.”BBC Science Focus Magazine